BloodScan Selected to Present at JPM Taipei 2026 Lightning Stage
BloodScan Selected to Present at JPM Taipei 2026 Lightning Stage
原文連結：
原文連結：
原文連結：
BloodScan is honored to have been selected to present at the Lightning Stage of the J.P. Morgan Healthcare Conference Taipei 2026, where we will showcase our latest advancements in cancer diagnostics.
Leveraging our proprietary Labyrinth Chip technology, BloodScan is advancing a new standard in label-free circulating tumor cell (CTC) enrichment, enabling more efficient approaches for ultra-early cancer detection and precision oncology research.
We sincerely appreciate the opportunity provided by J.P. Morgan and University of California, Berkeley, and are excited to share how BloodScan is contributing to the future of liquid biopsy innovation on a global stage.
BloodScan is honored to have been selected to present at the Lightning Stage of the J.P. Morgan Healthcare Conference Taipei 2026, where we will showcase our latest advancements in cancer diagnostics.
Leveraging our proprietary Labyrinth Chip technology, BloodScan is advancing a new standard in label-free circulating tumor cell (CTC) enrichment, enabling more efficient approaches for ultra-early cancer detection and precision oncology research.
We sincerely appreciate the opportunity provided by J.P. Morgan and University of California, Berkeley, and are excited to share how BloodScan is contributing to the future of liquid biopsy innovation on a global stage.